Months after AstraZeneca chief Pascal Soriot forced out MedImmune's head of clinical oncology development Mohammed Dar in a sweeping restructuring, the British drugmaker is ushering in Sunil Verma as head of breast cancer strategy as part of its oncology R&D wing, as it sharpens its focus on its keenly anticipated Daiichi Sankyo-partnered antibody-drug conjugate.
Buoyed by the performance of AstraZeneca's oncology drugs, in March Soriot bet big to partner with Daiichi Sankyo on its experimental breast cancer drug, with $1.35 billion upfront in a deal worth up to roughly $7 billion. Last week, the Japanese drugmaker said the therapy had cleared a pivotal mid-stage study, paving the way for regulatory submissions in the first half of fiscal 2019.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription